• Advances in hepatitis B therapeutics 

      Soriano, Vicente ; Barreiro, Pablo; Cachay, Edward R.; Kottilil, Shyamasundaran; Fernandez-Montero, José V.; Mendoza, Carmen de (Therapeutic Advances in Infectious Disease, 10/2020)
      Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
    • Envisioning a hepatitis delta cure with new antivirals 

      Soriano, Vicente ; Mendoza, Carmen de; Barreiro, Pablo; Treviño, Ana ; Corral, Octavio Jorge (Future Medicine Ltd., 2021)
      Envisioning a hepatitis delta cure with new antivirals
    • Oral antivirals for the prevention and treatment of SARS-CoV-2 infection 

      Soriano, Vicente; de Mendoza, Carmen; Edagwa, Benson; Treviño, Ana; Barreiro, Pablo; Fernandez-Montero, José V.; Gendelman, Howard E. (AIDS Reviews, 2022)
      Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease manifestations ...
    • Treatment of hepatitis delta and HIV infection 

      Soriano, Vicente; de Mendoza, Carmen; Treviño, Ana; Ramos-Rincón, José-Manuel; Moreno-Torres, Víctor; Corral, Octavio Jorge; Barreiro, Pablo (Liver International, 2023)
      Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...